[Skip to Content]
[Skip to Content Landing]
Other Articles
December 22, 1951


Author Affiliations


From the medical service of Robert W. Keeton, M.D., Research and Educational Hospitals, University of Illinois.

JAMA. 1951;147(17):1657. doi:10.1001/jama.1951.73670340006010e

Gantrisin® (3,4-dimethyl-5-sulfanilamido-isoxazole, also known as sulfisoxazole, and NU-445) is a relatively new sulfonamide which is now being widely used in the treatment of various bacterial infections, particularly those of the urinary tract. Recently, a case of agranulocytosis following the administration of this drug was reported.1 In a careful examination of the literature, the authors of this report were able to find only eight instances in which use of the drug had led to leucopenia.2 Most of the other investigators have emphasized the low toxicity of the compound. We wish herewith to report another instance of bone marrow depression presumably caused by gantrisin,® in order to reemphasize the possible dangers inherent in its use.

REPORT OF A CASE  E. L., aged 74, was first seen at the Research and Educational Hospitals, University of Illinois, for surgical treatment of benign prostatic hypertrophy and chronic pyelitis. At the time of his